An experimental rat model of ex vivo lung perfusion for the assessment of lungs after prostacyclin administration: Inhaled versus parenteral routes;Modelo experimental de perfusẽo pulmonar ex vivo em ratos: Avaliaç̃o de desempenho de pulmões submetidos à administração de prostaciclina inalada versus parenteral

Jornal Brasileiro de Pneumologia

Volumn 37, Issue 5, 2011, Pages 589-597

  Cardoso, Paulo Francisco Guerreiro ^a   Pazetti, Rogério ^a   Moriya, Henrique Takachi ^a   Pêgo Fernandes, Paulo Manuel ^a   de Almeida, Francine Maria ^a   Correia, Aristides Tadeu ^a   Fechini, Karina ^b   Jatene, Fabio Biscegli ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SANTO AMARO   (Brazil)

Author keywords

Animal; Lung transplantation; Models; Prostaglandins; Rats; Reperfusion

Indexed keywords

ANTIHYPERTENSIVE AGENT; PROSTACYCLIN;

ANIMAL; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BREATHING MECHANICS; DRUG EFFECT; GRAFT REJECTION; INFUSION; INHALATIONAL DRUG ADMINISTRATION; LUNG GAS EXCHANGE; LUNG TRANSPLANTATION; LUNG VENTILATION PERFUSION RATIO; MALE; METHODOLOGY; PHYSIOLOGY; PULMONARY ARTERY; RANDOMIZATION; RAT; STANDARD; WISTAR RAT;

ADMINISTRATION, INHALATION; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; EPOPROSTENOL; GRAFT REJECTION; INFUSIONS, PARENTERAL; LUNG TRANSPLANTATION; MALE; MODELS, ANIMAL; PULMONARY ARTERY; PULMONARY GAS EXCHANGE; RANDOM ALLOCATION; RATS; RATS, WISTAR; RESPIRATORY MECHANICS; VENTILATION-PERFUSION RATIO;

EID: 80155214237     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/S1806-37132011000500005     Document Type: Article

References (30)

1. de Perrot M, Keshavjee S. Lung preservation. Semin Thorac Cardiovasc Surg. 2004;16(4):300-8.
2. Quadri SM, Segall L, de Perrot M, Han B, Edwards V, Jones N, et al. Caspase inhibition improves ischemia-reperfusion injury after lung transplantation. Am J Transplant. 2005;5(2):292-9.
3. Tremblay LN, Yamashiro T, DeCampos KN, Mestrinho BV, Slutsky AS, Todd TR, et al. Effect of hypotension preceding death on the function of lungs from donors with nonbeating hearts. J Heart Lung Transplant. 1996;15(3):260-8.
4. Machherndl S, Kneussl M, Baumgartner H, Schneider B, Petkov V, Schenk P, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J. 2001;17(1):8-13.
5. Andrade CF, Martins LK, Tonietto TA, Koefender C, Anflor LC Jr, da Silva NB,et al. Partial liquid ventilation with perfluorodecalin following unilateral canine lung allotransplantation in non-heart-beating donors. J Heart Lung Transplant. 2004;23(2):242-51.
6. Ragaller M, Bleyl J, Tschö U, Winkler T, Regner M, Rasche S,et al. Effects of inhalation of perfluorocarbon aerosol on oxygenation and pulmonary function compared to PGI2 inhalation in a sheep model of oleic acid-induced lung injury. Intensive Care Med. 2001;27(5):889-97.
7. Cardoso PF, Spino M, Mayer E, Shi SQ, Pop RD, Puskas J, et al. Use of an isolated in situ canine lung perfusion model to evaluate dopamine clearance by the lung. J Pharmacol Exp Ther. 1991;259(3):1271-6.
8. Pêgo-Fernandes PM, Werebe Ede C, Cardoso PF, Pazetti R, Oliveira KA, Soares PR, et al. Experimental model of isolated lung perfusion in rats: technique and application in lung preservation studies. J Bras Pneumol. 2010;36(4):490-3.
9. Pêgo-Fernandes PM, Werebe E, Cardoso PF, Pazetti R, de Oliveira KA, Soares PR, et al. Experimental model of isolated lung perfusion in rats: first Brazilian experience using the IL-2 isolated perfused rat or guinea pig lung system. Transplant Proc. 2010;42(2):444-7.
10. Wittwer T, Wahlers T, Fehrenbach A, Elki S, Haverich A. Improvement of pulmonary preservation with Celsior and Perfadex: impact of storage time on early post-ischemic lung function. J Heart Lung Transplant. 1999;18(12):1198-201.
11. Soares PR, Braga KA, Nepomuceno NA, Pazetti R, Correia AT, Cardoso PF, et al. Comparison between Perfadex and locally manufactured low-potassium dextran solution for pulmonary preservation in an ex vivo isolated lung perfusion model. Transplant Proc. 2011;43(1):84-8.
12. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med. 2003;167(4):490-511.
13. De Perrot M, Sekine Y, Fischer S, Waddell TK, McRae K, Liu M, et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med. 2002;165(2):211-5.
14. Keshavjee SH, Yamazaki F, Cardoso PF, McRitchie DI, Patterson GA, Cooper JD. A method for safe twelve-hour pulmonary preservation. J Thorac Cardiovasc Surg. 1989;98(4):529-34.
15. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Jones DR, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg. 2002;73(4):1041-7; discussion 1047-8.
16. Suttorp N, Weber U, Welsch T, Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest. 1993;91(4):1421-8.
17. Mayer E, Puskas JD, Cardoso PF, Shi S, Slutsky AS, Patterson GA. Reliable eighteen-hour lung preservation at 4 degrees and 10 degrees C by pulmonary artery flush after high-dose prostaglandin E1 administration. J Thorac Cardiovasc Surg. 1992;103(6):1136-42.
18. de Perrot M, Fischer S, Liu M, Jin R, Bai XH, Waddell TK, et al. Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: a shift from pro-to anti-inflammatory cytokines. Transplantation. 2001;72(9):1505-12.
19. Kohmann J, Castro M, Silva U, Ruschel M, Madruga G, Felicetti J, et al. Efeito da prostaglandina E1 na viabilidade pulmonar de cadáver após transplante pulmonar unilateral em cães. J Pneumol. 1995;20(Suppl 3):145.
20. Wetzel RC. Aerosolized prostacyclin. In search of the ideal pulmonary vasodilator. Anesthesiology. 1995;82(6):1315-7.
21. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten SE. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest. 1998;114(3):780-6.
22. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet. 1993;342(8877):961-2.
23. Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J. 1997;10(5):1084-92.
24. Siobal M. Aerosolized prostacyclins. Respir Care. 2004;49(6):640-52.
25. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153(3):991-6.
26. Wittwer T, Franke UF, Sandhaus T, Thiene M, Groetzner J, Strauch JT, et al. Preischemic iloprost application for improvement of graft preservation: which route is superior in experimental pig lung transplantation: inhaled or intravenous? Transplant Proc. 2007;39(5):1345-9.
27. Wittwer T, Franke UF, Ochs M, Sandhaus T, Schuette A, Richter S, et al. Inhalative pre-treatment of donor lungs using the aerosolized prostacyclin analog iloprost ameliorates reperfusion injury. J Heart Lung Transplant. 2005;24(10):1673-9.
28. Puskas JD, Cardoso PF, Mayer E, Shi S, Slutsky AS, Patterson GA. Equivalent eighteen-hour lung preservation with low-potassium dextran or Euro-Collins solution after prostaglandin E1 infusion. J Thorac Cardiovasc Surg. 1992;104(1):83-9.
29. Wittwer T, Wahlers T, Fehrenbach A, Cornelius JF, Elki S, Ochs M, et al. Combined use of prostacyclin and higher perfusate temperatures further enhances the superior lung preservation by Celsior solution in the isolated rat lung. J Heart Lung Transplant. 1999;18(7):684-92.
30. Koller ME, Reed RK. Increased negativity of interstitial fluid pressure in rat trachea in dextran anaphylaxis. J Appl Physiol. 1992;72(1):53-7.